Rheumatoid Arthritis — Masterclass Module

📋

Overview & Learning Objectives

Epidemiology · Clinical Relevance · What you'll master today

~0.5–1%

Global prevalence of RA in adults

3:1

Female-to-male ratio

25–55 yrs

Peak incidence age range

🌍 Epidemiology Snapshot

Rheumatoid Arthritis (RA) is the most common form of chronic inflammatory arthritis, affecting approximately 0.5–1% of adults worldwide, with a global burden of ~18 million people. Per StatPearls 2023 / Harrison's 21e.

Global Burden

Prevalence varies geographically — Native American tribes (Pima, Chippewa) report rates up to 7%; Asia and Africa have lower rates (0.2–0.4%)
India: Estimated prevalence ~0.75% (~10 million affected); often presents late due to limited awareness
Incidence has remained relatively stable but disability burden has decreased due to modern DMARDs
More common in females — thought to be estrogen-mediated immune dysregulation
In some Latin American and African countries, female:male ratio reaches 6:1

Why RA Matters Clinically

🔴 Leading cause of inflammatory joint destruction — up to 50% of patients have significant disability within 10 years if undertreated
🔴 Systemic disease — extraarticular manifestations affect multiple organs; cardiovascular mortality 2× general population
🟡 Median life expectancy shortened by 7 years (men) and 3 years (women)
🟢 Completely reversible if diagnosed early and treated aggressively — "Treat-to-Target" revolution has transformed outcomes

🎯 Learning Objectives (Bloom's Taxonomy — L1 → L6)

L1

REMEMBER — Define RA and recall its epidemiology, demographics, and the 2010 ACR/EULAR classification criteria components
L2

UNDERSTAND — Explain the molecular pathogenesis of RA including the role of CD4+ T cells, B cells, TNF-α, IL-6, and pannus formation in joint destruction
L3

APPLY — Construct a diagnostic algorithm for a patient presenting with symmetrical polyarthritis, applying classification criteria and appropriate investigations
L4

ANALYZE — Differentiate RA from other inflammatory arthritides using clinical, serological, imaging, and histological data
L5

EVALUATE — Formulate a EULAR 2025 guideline-aligned treatment plan for early, established, and refractory RA including special populations
L6

CREATE — Design a comprehensive monitoring strategy incorporating disease activity scores (DAS28/CDAI/SDAI), drug toxicity surveillance, and a Treat-to-Target approach with patient counseling

🔵 Module Promise

After completing this module you will confidently diagnose RA in the clinic, score disease activity at the bedside, sequence DMARDs per 2025 EULAR guidance, counsel patients on methotrexate, biologics, and JAK inhibitors, and identify life-threatening extraarticular complications — putting you in the top 5% of medical graduates globally on this topic.

➡️ Next up: Section 2 — Pathogenesis. We'll dissect the synovium at the molecular level and show you exactly how genetics, environment, and immune dysregulation converge to destroy cartilage and bone.

🔬

Pathogenesis

Molecular mechanisms · Genetics · Cytokine cascade · Joint destruction

🧬 Genetic Architecture of RA

RA is a multifactorial disease with heritability estimated at 40–65%. Genetic factors account for ~50% of the risk in ACPA-positive RA.

HLA-DRB1 — The Shared Epitope (SE)

The strongest genetic association is with MHC Class II alleles, particularly HLA-DRB1. The SE is a conserved amino acid sequence (positions 70–74) in the third hypervariable region of the HLA-DR β-chain. Per Harrison's 21e, Chapter 358.

SE alleles: HLA-DRB1*0401, *0404, *0101 (European); *0405, *0901 (Asian)
The SE promotes peptide binding and T-cell activation — particularly citrullinated peptides
Carriers of 2 SE alleles have much higher disease risk and worse outcomes than 1 or no SE

Non-HLA Genetic Loci (GWAS Discoveries)

PTPN22 — Encodes lymphoid tyrosine phosphatase; gain-of-function → impaired self-tolerance; common in Europeans
PADI4 — Encodes PAD4 enzyme; converts arginine → citrulline; strongly associated with ACPA+ RA in East Asians
TNFAIP3 / TRAF1-C5 / CTLA4 — B-cell and T-cell signaling pathways
STAT4 / BTLA / ELMOI — Cytokine and cell migration regulation

🌍 Environmental Triggers

Cigarette Smoking — Most reproducible environmental risk; 1.5–3.5× increased RA risk; synergizes with SE alleles up to 40-fold; activates PAD enzymes in lung → citrullination → ACPA generation
Periodontitis / P. gingivalis — Only oral bacterium expressing PAD enzyme → generates citrullinated antigens → may initiate ACPA response years before joint symptoms
Gut microbiome — Dysbiosis (↑ Prevotella copri in early RA); exact mechanism unclear
Epigenetic factors — DNA methylation differences between RA and OA patients; miR146a implicated in synovial fibroblast activation

The autoimmune process in RA begins 10+ years before joint symptoms — RF and ACPA are detectable in serum long before arthritis develops. This pre-RA window is the focus of current prevention research.

⚙️ Pathogenesis Flowchart — Step by Step

STEP 1: INITIATION Environmental trigger (smoke, periodontal disease, gut dysbiosis) └─▶ PAD enzyme activation in mucosal surfaces └─▶ Citrullination of fibrinogen, vimentin, collagen, keratin └─▶ Neoantigens formed = citrullinated peptides (CCPs) STEP 2: ADAPTIVE IMMUNE ACTIVATION Antigen-Presenting Cells (APCs) present citrullinated peptides via HLA-DR (SE alleles) └─▶ CD4+ T cells activated via TCR-MHC peptide (Signal 1) + CD28-CD80/86 (Signal 2) ├─▶ Th1 cells → IFN-γ, TNF-α, lymphotoxin-β → macrophage activation └─▶ Th17 cells → IL-17A, IL-17F, GM-CSF → neutrophil recruitment STEP 3: B CELL ACTIVATION & AUTOANTIBODY PRODUCTION CD4+ Th cells (via CD40L-CD40) → B cell activation → Plasma cells └─▶ RF (IgM anti-IgG Fc) — +ve in ~70% RA └─▶ Anti-CCP antibodies (ACPA) — +ve in ~67%; specificity ~97% └─▶ Immune complex formation → Complement activation → Synovial inflammation STEP 4: SYNOVIAL INFLAMMATION (PANNUS FORMATION) Inflamed synovium produces: ├─▶ TNF-α → adhesion molecules ↑, leukocyte influx, prostaglandins ↑, IL-1↑, IL-6↑ ├─▶ IL-6 → acute phase response (CRP↑, ESR↑), B cell differentiation, anemia ├─▶ IL-1 → cartilage degradation, MMP expression, fever └─▶ IL-17 → neutrophil activation, further bone loss Synovial fibroblasts proliferate → PANNUS — invasive granulation tissue └─▶ Secrets MMPs (matrix metalloproteinases) → CARTILAGE DEGRADATION STEP 5: BONE DESTRUCTION RANK-L (from synoviocytes, T cells, fibroblasts) + M-CSF └─▶ Differentiation of Pre-OC → Osteoclasts └─▶ Cathepsin K secretion → BONE EROSION TNF-α inhibits Wnt pathway (via DKK-1 upregulation) └─▶ Osteoblast suppression → Impaired bone formation Result: NET BONE LOSS = EROSIONS

CITRATE

CCitrullination — PAD4 converts arginine to citrulline; generates ACPAs

IImmune activation — CD4+ T cells (Th1/Th17), B cells, plasma cells, macrophages

TTNF-α + IL-6 + IL-17 — The triad of inflammatory cytokines driving RA

RRANKL activation — Drives osteoclastogenesis → bone erosions

AAutoantibodies — RF and ACPA; can precede disease by ≥10 years

TT-cell dysregulation — Loss of self-tolerance; Tregs deficient in RA

EErosion — Pannus + MMPs + Osteoclasts = irreversible joint destruction

🔑 Key Cytokines & Their Clinical Targets

Cytokine	Key Actions in RA	Therapeutic Target
TNF-α	Upregulates adhesion molecules, stimulates IL-1/IL-6/MMP; central amplifier	Anti-TNF biologics (adalimumab, etanercept, infliximab, etc.)
IL-6	Acute phase response (CRP↑), synovitis, anemia, T/B cell differentiation, osteoclast activation	Tocilizumab, Sarilumab (IL-6R inhibitors)
IL-1	Cartilage catabolism, fever, MMP induction	Anakinra (IL-1RA)
IL-17	Neutrophil recruitment, RANKL upregulation, synovitis	Secukinumab (NOT approved for RA; more for SpA)
GM-CSF	Monocyte/macrophage differentiation, inflammation amplification	Under investigation
RANKL	Osteoclast differentiation → bone erosions	Denosumab (adjunct for osteoporosis in RA)
JAK/STAT pathway	Intracellular signaling for multiple cytokines (IL-6, IL-12, IL-23, IFN-γ)	JAK inhibitors (tofacitinib, baricitinib, upadacitinib)

⚡ Rapid Fire — Pathogenesis

The "shared epitope" is in HLA-DRB1 at positions 70–74 of the β-chain — critical for peptide presentation
PADI4 encodes the enzyme that citrullinates proteins → the molecular basis of ACPA
Smoking confers 40× risk when combined with SE alleles — the strongest gene-environment interaction in RA
RF is not specific — also +ve in SLE, Sjögren's, chronic infections; ACPA is specific (~97%)
The pannus is invasive fibrovascular tissue from the synovium that directly destroys cartilage and bone
DKK-1 (upregulated by TNF) blocks Wnt signaling → suppresses osteoblasts → bone cannot regenerate after erosion

➡️ Next up: Section 3 — Clinical Features. We'll map every articular and extraarticular manifestation using the RHEUMATOID mnemonic, and present the "classic patient" you'll meet in the exam and clinic.

🩻

Clinical Features

Articular · Extraarticular · Classic vignette · Red flags

🟢 Classic Exam Vignette

A 42-year-old female presents with a 3-month history of swelling and pain in both hands, affecting the MCPs and PIPs symmetrically, with morning stiffness lasting 2 hours that improves with activity. She notices her grip has weakened — she now struggles to open jar lids. On examination: boggy synovitis of bilateral MCPs, ulnar deviation of fingers, positive squeeze test. ESR 78 mm/hr, CRP 42 mg/L, RF 1:320, Anti-CCP positive. This is RA until proven otherwise.

🦴 Articular Features

RHEUMATOID

RRheumatoid nodules — subcutaneous, firm, at pressure points (olecranon, sacrum, Achilles); 30–40% of patients; RF-positive patients more commonly

HHand deformities — boutonnière, swan-neck, Z-thumb; MCP subluxation with ulnar deviation; "piano key" sign of ulnar styloid

EEye disease — Keratoconjunctivitis sicca (2° Sjögren's), episcleritis, scleritis (rarely scleromalacia perforans)

UUlnar deviation (at MCPs) + Ulnar styloid erosion — classic X-ray finding; also "caput ulnae" syndrome

MMorning stiffness > 1 hour — hallmark of inflammatory arthritis; improves with activity (gel phenomenon)

AAtlantoaxial subluxation 🔴 — C1-C2 instability; risk of cord compression; MUST check before GA/intubation; Anaemia of chronic disease (most common haematologic)

TTenosynovitis — flexor tendon sheaths; trigger finger; carpal tunnel syndrome (median nerve compression)

OOsteoporosis — periarticular early → generalized; glucocorticoids compound this; fragility fractures

IILD (Interstitial Lung Disease) — UIP and NSIP patterns; 3–12% prevalence; ILD with smoking = highest risk

DDeformities + Disability — end-stage joint destruction; PIP = swan-neck/boutonnière; DIP = Z-line deformity

Specific Joint Involvement — Patterns

Joint	Pattern	Classic Deformity / Feature
MCP joints	Early, bilateral, symmetric	Volar subluxation + ulnar deviation
PIP joints	Bilateral, early	Swan-neck (PIP hyperextension, DIP flexion) or Boutonnière (PIP flexion, DIP hyperextension)
Wrists	Very frequent; "caput ulnae"	Subluxation, carpal tunnel, piano-key sign
MTP joints	Feet — lateral aspect of 5th MTP first	"Cock-up" deformities; subluxation, calluses
Knee	Synovial effusion common	Baker's cyst (popliteal); can rupture → DVT mimic 🚩
Cervical spine (C1-C2)	Atlantoaxial subluxation	🔴 Cord compression risk — check BEFORE intubation
DIP joints	Typically spared (unlike OA/PsA)	Involvement suggests PsA or OA
Lumbar/thoracic spine	Typically spared	Involvement suggests SpA

🫀 Extraarticular Manifestations (EAMs) — Up to 40% of Patients

⚠️ Risk Factors for EAMs

EAMs more common in patients with: high-titre RF/ACPA, heavy smoking history, severe joint disease, early onset, male sex. Subcutaneous nodules = high-RF patient. ILD = smoker + high RF.

System	Manifestation	Notes / High-Yield
Skin	Rheumatoid nodules (30–40%), purpura, pyoderma gangrenosum	Nodules at pressure points; can occur in lungs/pleura (Caplan's syndrome with pneumoconiosis)
Pulmonary	Pleural effusions, ILD (UIP/NSIP), pulmonary nodules, pulmonary vasculitis, organizing pneumonia	ILD prevalence 3–12%; can precede arthritis; screen with HRCT. Leflunomide/MTX can worsen ILD 🔴
Cardiovascular	Pericarditis, myocarditis, CAD (2×↑), cardiomyopathy, mitral regurgitation	🔴 #1 cause of death in RA is cardiovascular disease
Ocular	KCS (2° Sjögren's), episcleritis, scleritis	Scleromalacia perforans = painless blue-grey thinning → perforation risk
Neurological	Peripheral neuropathy, mononeuritis multiplex, cervical myelopathy (C1-C2)	Atlantoaxial subluxation — Lhermitte's sign; check before GA
Haematological	Anaemia of chronic disease (#1), thrombocytosis, neutropenia, Felty's syndrome, T-LGL	Felty's = RA + splenomegaly + neutropenia 💡 (Triad)
Renal	Membranous nephropathy, secondary amyloidosis (AA amyloid)	Drug toxicity (NSAIDs, gold) also common renal issues
Endocrine	Hypoandrogenism in males	Low testosterone correlates with disease activity
GI	Vasculitis	Rare; suggests active systemic disease
Lymphoma	2–4× increased risk (diffuse large B-cell)	Risk ↑ with Felty's syndrome and high disease activity
Sjögren's (2°)	Xerostomia (dry mouth) + KCS (dry eyes) — 10% of RA	Distinguish from 1° Sjögren's
Vasculitis	Cutaneous (palpable purpura, ulcers, nail fold infarcts), mononeuritis multiplex	Decreasing incidence with modern DMARDs; suggests severe disease

🔴 RED FLAGS — Do NOT Miss in RA

🔴 Fever >38.3°C in RA patient → Think INFECTION first (septic arthritis, opportunistic), not flare
🔴 Neck pain with myelopathy signs (upper limb weakness, Lhermitte's) → Atlantoaxial subluxation — URGENT imaging
🔴 Acute red eye with photophobia → Scleritis not conjunctivitis; vision-threatening
🔴 Progressive dyspnoea on exertion in RA patient → ILD / pericardial effusion / pulmonary hypertension
🔴 Hot, red, swollen single joint in RA → Septic arthritis until proven otherwise (aspirate immediately)
🔴 Calf swelling after knee flare → Ruptured Baker's cyst mimics DVT — ultrasound mandatory

⚡ Rapid Fire — Clinical Features

Morning stiffness >1 hour = inflammatory; <30 min = OA
RA involves MCPs and PIPs but SPARES DIPs (unlike OA); SPARES SI joints (unlike SpA)
Felty's syndrome = RA + splenomegaly + neutropenia — ↑lymphoma risk
Most common cause of death in RA = Cardiovascular disease (not infection)
Atlantoaxial subluxation occurs in <10% of patients now (down from 20–30% in pre-DMARD era)
ILD precedes arthritis in some patients — seronegative does NOT mean no ILD risk

➡️ Next up: Section 4 — Diagnostic Approach. The step-by-step algorithm from "joint pain" to "definite RA," including the 2010 ACR/EULAR classification criteria decoded.

🧪

Diagnostic Approach

Algorithm · Labs · Imaging · 2010 ACR/EULAR Criteria · Pitfalls

🔍 Step-by-Step Diagnostic Algorithm

PATIENT PRESENTS: Joint pain + swelling │ ▼ STEP 1: HISTORY — Key Questions ├─ Symmetrical? Small joints (MCP, PIP, wrist, MTP)? ├─ Morning stiffness > 1 hour? (Gel phenomenon) ├─ Duration > 6 weeks? (Chronicity criterion) ├─ DIP joints spared? (RA spares DIP; OA/PsA do not) ├─ Family history of autoimmune disease? └─ Smoking history? Preceding oral/chest symptoms? │ ▼ STEP 2: PHYSICAL EXAMINATION ├─ Boggy synovitis (soft, fluctuant swelling — synovial fluid + thickened synovium) ├─ Squeeze test (MCP/MTP) — tenderness on lateral compression = positive ├─ Subcutaneous nodules at pressure points? ├─ Extra-articular features? (eye, chest, skin, lymph nodes) └─ Deformities suggesting established disease? │ ▼ STEP 3: INVESTIGATIONS ┌────────────────────────────────────────────────────────────────┐ │ SEROLOGY: │ │ RF (IgM): Sens 70%, Spec ~75% → NOT diagnostic alone │ │ Anti-CCP (ACPA): Sens ~67%, Spec ~97% → Most specific test │ │ ANA: +ve ~30% (low titre); rules out SLE if high titre │ │ INFLAMMATORY MARKERS: │ │ CRP + ESR: Elevated in active disease; correlate activity │ │ Note: IL-6 inhibitors & JAKi blunt CRP even without remission│ │ HAEMATOLOGY: │ │ CBC: Normochromic normocytic anaemia; thrombocytosis │ │ WBC: Usually normal unless Felty's (↓) or infection │ │ OTHER: │ │ LFTs, Creatinine (baseline before DMARDs) │ │ Hepatitis B/C serology (before biologics/MTX) │ │ Quantiferon/Mantoux (before biologics — latent TB screen) │ └────────────────────────────────────────────────────────────────┘ │ ▼ STEP 4: APPLY 2010 ACR/EULAR CLASSIFICATION CRITERIA (Score ≥ 6/10 = Definite RA for clinical trials) See detailed criteria table below │ ▼ STEP 5: IMAGING ├─ X-ray hands & feet: First-line; periarticular osteopenia, erosions, JSN ├─ Ultrasound (power Doppler): Synovitis, tenosynovitis, early erosions; portable └─ MRI: Gold standard for early bone marrow oedema and pre-erosive changes │ ▼ DIAGNOSIS CONFIRMED → INITIATE TREAT-TO-TARGET Start MTX + short-term GC within weeks of diagnosis Target: DAS28 < 2.6 (Remission) or < 3.2 (Low Disease Activity) (Per EULAR 2025 Recommendation #1: Start DMARDs immediately on diagnosis)

📊 2010 ACR/EULAR Classification Criteria

⚠️ Classification ≠ Diagnostic Criteria

Per EULAR 2025: Classification criteria are for research, not diagnosis. Diagnosis is clinical. A patient can have RA with <6 points if the rheumatologist judges clinical synovitis is present.

Domain	Finding	Score
A. Joint Involvement (swollen or tender)	1 large joint (shoulder, elbow, hip, knee, ankle)	0
	2–10 large joints	1
	1–3 small joints (MCP, PIP, MTP, wrist, 2nd-5th MTP)	2
	4–10 small joints	3
	>10 joints (at least 1 small joint)	5
B. Serology	Negative RF AND negative ACPA	0
	Low positive RF OR low positive ACPA (<3× ULN)	2
	High positive RF OR high positive ACPA (≥3× ULN)	3
	Anti-CCP preferred over RF for specificity
C. Acute Phase Reactants	Normal CRP AND normal ESR	0
C. Acute Phase Reactants	Abnormal CRP OR abnormal ESR	1
D. Duration of Symptoms	<6 weeks	0
D. Duration of Symptoms	≥6 weeks	1
🟢 Score ≥6/10 = Definite RA		Max: 10

Note: Applies to patients with ≥1 clinically swollen joint not better explained by another diagnosis. Source: Aletaha D et al, Arthritis Rheum 2010.

🖼️ Imaging Findings in RA

Modality	Key Findings	Sensitivity / Specificity	Clinical Use
X-ray (plain radiograph)	Periarticular osteopenia, soft tissue swelling (early); erosions, joint space narrowing, subluxation (late)	Low sensitivity for early disease (~25%)	First-line; monitoring progression; diagnostic late
Ultrasound (Power Doppler)	Synovial thickening, joint effusion, tenosynovitis, early erosions, vascularity (active inflammation)	More sensitive than X-ray for synovitis and early erosions	Bedside, no radiation; evaluate response to treatment; guide injection
MRI	Bone marrow oedema (pre-erosive!), synovitis, tenosynovitis, erosions (best visualization)	Gold standard for early erosion detection; Spec ~80–90%	Early disease when X-ray negative; cervical spine (C1–C2 stability)
CT	Lung (HRCT for ILD — UIP, NSIP patterns), erosions in small bones	Gold standard for ILD characterization	Pulmonary complications; surgical planning

X-ray finding sequence in RA: Soft tissue swelling → Periarticular osteopenia → Joint space narrowing → Erosions → Subluxation/deformity. Erosions are a poor prognostic sign — they indicate established structural damage.

🔬 Laboratory Interpretation Pearls

💡 RF negative in ~30% of RA — "seronegative RA" is still RA if other criteria met; check anti-CCP
💡 Anti-CCP appears 10+ years before symptoms — highly predictive of RA development in at-risk individuals
💡 RF positive in many other conditions: SLE, Sjögren's, HCV, SBE, TB, Waldenström's, normal elderly — do NOT diagnose RA on RF alone
💡 Synovial fluid in RA: WBC 2,000–50,000/μL (inflammatory); predominantly PMN neutrophils; glucose mildly low; complement low
💡 ESR/CRP interpretation with IL-6 inhibitors and JAKi — CRP is markedly suppressed independently of clinical response; use joint counts (DAS28-CRP may be falsely low)
💡 Anti-CCP + RF together: If both positive, specificity for RA approaches 99%

⚡ Rapid Fire — Diagnosis

Anti-CCP specificity = ~97% — most specific test in RA
Score ≥6/10 on 2010 ACR/EULAR = Definite RA
MRI detects bone marrow oedema before erosions form — the earliest structural warning sign
Power Doppler US: vascularity = active synovitis; guides injection and treatment decisions
Seronegative RA = RF and anti-CCP both negative in ~10% of RA patients

➡️ Next up: Section 5 — Differentials & Pitfalls. The 5 conditions that mimic RA perfectly, and the clues that help you escape the diagnostic trap.

⚖️

Differentials & Pitfalls

Top mimics · Distinguishing features · Do-not-miss diagnoses

Condition	Similarities to RA	Key Distinguishing Features	Clincher Test
Osteoarthritis (OA)	Joint pain, stiffness	Morning stiffness <30 min; affects DIPs (Heberden's) and 1st CMC; bony swelling; no systemic features; normal CRP/ESR	X-ray: osteophytes, sclerosis (no erosions)
Psoriatic Arthritis (PsA)	Polyarthritis, RF may be negative	DIP involvement; "sausage digits" (dactylitis); enthesitis; psoriatic skin/nail changes; often seronegative; asymmetric; sacroiliitis	Skin/nail examination; X-ray: "pencil in cup" deformity; SI joint imaging
SLE Arthritis	Symmetrical small joint polyarthritis, positive ANA	Jaccoud's arthropathy (reducible — ligament laxity, not erosive); rash (malar, photosensitive); multi-organ; anti-dsDNA, low C3/C4	Anti-dsDNA (specific for SLE); complement levels; urinalysis
Reactive Arthritis (ReA)	Acute joint swelling, young adults	Follows infection (GI or urogenital); asymmetric; large joints; Reiter's triad: urethritis + conjunctivitis + arthritis; self-limiting; HLA-B27 positive	Preceding infection history; HLA-B27; STI/GI culture
Gout / Pseudogout	Joint swelling, pain	Episodic, asymmetric; gout = MTP-1 (podagra), uric acid crystals; pseudogout = large joints (knee), chondrocalcinosis on X-ray; serum uric acid (not diagnostic alone)	🔴 JOINT ASPIRATION — MSU crystals (needle, negatively birefringent) or CPPD crystals (rhomboid, weakly +ve birefringent)
Polymyalgia Rheumatica (PMR)	Elderly, stiffness, elevated ESR/CRP, RF can be low-positive	Age >50; proximal girdle (shoulder, hip) stiffness; NO small joint synovitis; dramatic response to low-dose prednisolone; associated GCA	Age, proximal pattern, dramatic response to prednisone 15–20 mg/day
Viral Arthritis	Symmetrical polyarthritis, RF+ possible	Parvovirus B19: "slapped cheek" rash, transient (<6 weeks); HCV: chronic, low-titre RF; Rubella; Chikungunya (epidemic, acute)	Serology (anti-B19 IgM, HCV PCR); symptoms usually resolve

🔴 Do NOT Miss

🔴 Septic Arthritis — A hot, swollen joint in an RA patient on DMARDs/biologics is infected until proven otherwise. Aspirate immediately. Delay = joint destruction + sepsis
🔴 Malignancy — Paraneoplastic arthritis can mimic RA. In seronegative elderly with atypical features, consider lymphoma, solid tumours
🔴 RS3PE Syndrome — Remitting, seronegative symmetric synovitis with pitting oedema; elderly males; responds to low-dose prednisone; rule out underlying malignancy
🔴 Adult-onset Still's disease (AOSD) — Quotidian fever + salmon-coloured rash + arthritis + ferritin >10,000 ng/mL. Seronegative. Can be fatal if untreated

⚠️ Classic Diagnostic Pitfalls in RA

Diagnosing RA based on RF alone — RF is positive in SLE, Sjögren's, HCV, SBE, and 5% of normals. Always confirm with anti-CCP + clinical criteria
Missing seronegative RA — ~10% of RA has negative RF AND anti-CCP. Clinical synovitis + criteria = diagnosis
Attributing all joint pain in RA to the disease — RA patients get OA, gout, septic arthritis, AVN (from steroids). Investigate each new complaint
Waiting for erosions before starting DMARDs — Erosions are irreversible. Treat EARLY and aggressively
Fibromyalgia co-existing with RA — Pain out of proportion to joint count? Consider FM overlay — avoid escalating DMARDs inappropriately

⚡ Rapid Fire — Differentials

RA spares DIP joints → DIP involvement = OA (Heberden's), PsA, or erosive OA
Single hot joint in RA patient on biologics = septic arthritis until aspirated
Jaccoud's arthropathy (SLE) = reducible; RA deformities are fixed
"Pencil in cup" deformity on X-ray = Psoriatic Arthritis
RS3PE = pitting oedema of hands + seronegative symmetric synovitis + elderly → rule out malignancy

➡️ Next up: Section 6 — Management. The EULAR 2025 three-phase algorithm, from methotrexate to biologics to JAK inhibitors, decoded step by step.

💊

Management

EULAR 2025 algorithm · DMARDs · Biologics · JAKi · Special populations

🔵 EULAR 2025 Core Principles (5 Overarching Principles)

A. Treatment aimed at best care; must involve shared decision-making
B. Decisions based on disease activity, safety, comorbidities, and structural progression
C. Rheumatologists are the primary specialists caring for RA patients
D. Access to multiple DMARDs with different mechanisms is required (heterogeneity of RA)
E. RA incurs high individual, medical, and societal costs — consider in management

🗺️ EULAR 2025 Treatment Algorithm — 3 Phases

Phase I

First Treatment Strategy (Recommendation #4, 5)

For all newly diagnosed RA patients

Methotrexate (MTX)

Anchor DMARD — first choice for ALL RA patients without contraindication

10–25 mg/week PO or SQ | Folic acid 5 mg/week co-prescribed always

Monitor: CBC, LFTs, creatinine every 4 weeks × 3 months, then every 3 months

Toxicity: Hepatotoxicity, myelosuppression, ILD (rare), stomatitis, teratogenicity

Short-term GC

Bridging therapy while MTX takes effect (onset 6–12 weeks); different routes/doses

Prednisolone 5–20 mg/day PO, IM methylprednisolone, or intraarticular

Taper as rapidly as clinically feasible; target: STOP within 3–6 months

Osteoporosis, hyperglycaemia, HTN, infections, cataracts, adrenal suppression

Alternatives to MTX

If MTX contraindicated or intolerated:

Leflunomide 10–20 mg/day OR Sulfasalazine 1–1.5 g twice daily

✅ EVALUATE AT 3 MONTHS & 6 MONTHS

If ≥50% improvement at 3 months AND target reached at 6 months → Continue Phase I ± dose reduction in sustained remission. If NOT → Proceed to Phase II.

Phase II

Add a bDMARD — After csDMARD Failure (Recommendation #6, 7)

Key 2025 change: Remove prognostic factor stratification — MTX failure itself is a bad prognostic sign

⚠️ 2025 EULAR Key Change

Previous versions stratified patients by risk factors (RF+, erosions, high disease activity) to guide Phase II choice. The 2025 task force removed this stratification — MTX failure alone is now sufficient indication for bDMARD. This reflects declining biosimilar costs and evidence that second csDMARD has poor persistence.

Biologics (bDMARDs) — First Choice

Drug	Class	Dose / Route	Key Points
Adalimumab	Anti-TNF	40 mg SQ every 2 weeks	Biosimilars widely available; most used globally
Etanercept	Anti-TNF (TNF-R fusion)	50 mg SQ weekly or 25 mg biweekly	Approved as monotherapy; less TB reactivation risk
Infliximab	Anti-TNF	3 mg/kg IV at 0,2,6 weeks, then q8w	IV; can increase dose to 10 mg/kg
Certolizumab pegol	Anti-TNF (PEGylated Fab)	400 mg SQ at 0,2,4 weeks; then 200 mg q2w	Safe in pregnancy (no placental transfer)
Golimumab	Anti-TNF	50 mg SQ monthly	Monthly dosing — convenience
Tocilizumab	Anti-IL-6R	4–8 mg/kg IV monthly OR 162 mg SQ q1–2w	Good for RA-ILD; CRP unreliable for monitoring
Sarilumab	Anti-IL-6R	200 mg SQ every 2 weeks	Monotherapy approved; good if can't use csDMARD
Abatacept	CTLA4-Ig (T-cell co-stimulation blocker)	Weight-based IV monthly OR 125 mg SQ weekly	Good safety profile; preferred in chronic lung disease
Rituximab	Anti-CD20 (B-cell depletion)	1000 mg IV × 2 doses (day 0 and 14); repeat q24w	Preferred in: seronegative + lymphoma history + HCV; risk of PML
Anakinra	IL-1RA	100 mg SQ daily	Less efficacious; used for AOSD, Muckle-Wells, Still's

JAK Inhibitors (tsDMARDs) — Consider After Risk Assessment

🔴 JAK Inhibitor Safety — CRITICAL Per EULAR 2025

JAKi are at the same algorithmic level as bDMARDs but require careful risk assessment. Use with caution in patients with: age >65, current or past smoking, other CV risk factors (diabetes, obesity, HTN), history of malignancy, prior thrombosis, history of NMSC, or taking hormonal contraceptives. Based on ORAL Surveillance trial (tofacitinib vs anti-TNF in high-CV risk RA): ↑MACE, ↑malignancy, ↑VTE risk. Most observational data have NOT consistently confirmed these risks — use clinical judgment.

Drug	JAK Selectivity	Dose	Monitoring
Tofacitinib	JAK1/JAK3 (minor JAK2)	5 mg PO twice daily OR 11 mg extended-release once daily	CBC, LFTs, lipids; check lipids at 4–8 weeks
Baricitinib	JAK1/JAK2	4 mg PO once daily (2 mg if renal impairment/elderly)	Same as tofacitinib; watch platelets (JAK2 inhibition)
Upadacitinib	Preferential JAK1	15 mg PO once daily	CBC, LFTs, lipids; herpes zoster prophylaxis in high-risk
Filgotinib	Preferential JAK1	200 mg PO once daily	Spermatogenesis concern (avoid in men trying to conceive)

All JAKi: Contraindicated in pregnancy. Screen for latent TB before starting. Risk of herpes zoster — consider prophylaxis. Check VTE risk.

Phase III

Change bDMARD or JAKi — After Phase II Failure (Recommendation #8)

Switch within class or to different mechanism

If anti-TNF fails: Switch to another anti-TNF OR different class (abatacept, rituximab, IL-6Ri, JAKi)
If 1 TNF inhibitor fails: Second anti-TNF is a valid option (class switch not mandatory)
If primary failure (no response): Prefer switching to a different mechanism of action
If secondary failure (loss of response after initial benefit): Causes include immunogenicity, inadequate dosing, adherence — TDM can help (though EULAR 2025 states TDM is NOT routinely needed)
Cycling between JAKi after JAKi failure: Positive observational data — acceptable approach

Remission Phase

Tapering in Sustained Remission (Recommendation #9)

EULAR 2025: DO NOT STOP — TAPER

🔴 Critical 2025 Update

Previous EULAR recommended "consider stopping" in remission. 2025 update strengthened this: Stopping DMARDs leads to flares in the vast majority within 1 year. New language: Continue DMARDs but dose reduction/interval increase may be considered after ≥6 months of sustained remission. GCs must be discontinued before tapering advanced therapy.

Tapering hierarchy: First taper GC → then taper/space bDMARD or JAKi → lastly taper csDMARD (MTX). Never abruptly stop.

💊 Full DMARD Reference Table

Drug	Dose	Serious Toxicities	Initial Eval	Monitoring
Hydroxychloroquine	200–400 mg/day (≤5 mg/kg)	Irreversible retinal damage, cardiotoxicity, blood dyscrasia	Eye exam if >40 yrs	Optical coherence tomography yearly
Sulfasalazine	500 mg twice daily → 1–1.5 g twice daily	Granulocytopenia, haemolytic anaemia (G6PD def)	CBC, LFTs, G6PD	CBC q2–4w × 3 months, then q3 months
Methotrexate	10–25 mg/week PO/SQ + folic acid 5 mg/week	Hepatotoxicity, myelosuppression, ILD, teratogen (Preg Cat X)	CBC, LFTs, creatinine, CXR, viral hepatitis panel	CBC + LFTs q4–6w initially, then q8–12w
Leflunomide	10–20 mg/day	Hepatotoxicity, myelosuppression, teratogen (X), peripheral neuropathy	CBC, LFTs, viral hepatitis panel	CBC + LFTs q2–3 months
Anti-TNF agents	(See above)	↑Bacterial infections, TB reactivation, ↑lymphoma risk (controversial), drug-induced lupus, demyelination	TB screening, hepatitis B/C, CBC	LFTs periodically; watch injection site reactions
Abatacept	Weight-based IV or 125 mg SQ weekly	↑Bacterial/viral infections	TB screening	Monitor infusion reactions
Rituximab	1000 mg IV × 2 (0 and 14 days); repeat q24w	↑Infections, infusion reactions, PML (rare), HBV reactivation	CBC, viral hepatitis panel	CBC regularly; consider prophylaxis
Tocilizumab	4–8 mg/kg IV monthly OR 162 mg SQ q1–2w	Infections, ↑LFTs, neutropenia, dyslipidaemia	TB screening, LFTs, CBC, lipids	CBC, LFTs at regular intervals; lipids
JAK inhibitors	(See above)	↑Infections, herpes zoster, MACE (tofacitinib high-risk), VTE, dyslipidaemia, malignancies (long-term)	TB screening, CBC, LFTs, lipids, creatinine	CBC, LFTs, lipids at regular intervals

MANAGE RA

MMethotrexate first — the anchor DMARD of all RA treatment

AAdd GC short-term as bridging while MTX takes effect (6–12 weeks)

NNavigate to bDMARD (anti-TNF/IL-6Ri/abatacept/rituximab) if Phase I fails

AAssess risk factors before JAK inhibitors (CV, malignancy, VTE, age)

GGoal = Remission (DAS28 <2.6) — check at 3 and 6 months; switch if not reached

EEscalate then Taper — don't stop DMARDs in remission; taper dose/interval only

👥 Special Populations

🤰 Pregnancy

RA often improves in pregnancy (75% of women) but flares postpartum
Safe: Hydroxychloroquine, sulfasalazine (+ folate), low-dose prednisone, certolizumab pegol (no placental transfer — preferred biologic in pregnancy)
Contraindicated: MTX (Category X — stop 3 months before conception), leflunomide (Category X — need washout with cholestyramine), all JAK inhibitors
Anti-TNF (except certolizumab) — consider risk/benefit; generally safe through 2nd trimester; avoid in 3rd trimester due to placental transfer

👴 Elderly Patients (>65 years)

Same efficacy of conventional DMARDs and biologics; increased infection risk
MTX dose may need adjustment for declining renal function (avoid if CrCl <30)
JAKi with extra caution in elderly (higher baseline CV/malignancy risk)
Fall risk → bone protection mandatory if on GC; FRAX calculation

🫁 RA-ILD

Avoid MTX and leflunomide in established ILD (lung toxicity risk)
Preferred DMARDs: Hydroxychloroquine, abatacept (may slow ILD progression), rituximab
EULAR 2025: Nintedanib may slow lung function decline in RA-ILD (subanalyses of INBUILD trial) — consult pulmonology

💉 Before Starting Biologics/JAKi — Mandatory Pre-treatment Screening

TB screening: QuantiFERON Gold or Mantoux; if positive → treat latent TB (isoniazid 9 months) THEN start biologic
Hepatitis B/C serology; HBsAg+ → antiviral prophylaxis before anti-TNF/rituximab
Live vaccines: Administer all live vaccines ≥4 weeks BEFORE starting biologics; NO live vaccines WHILE on biologics
NMSC screening before JAKi (slightly elevated risk)

🏃 Non-Pharmacological Management

Exercise: Dynamic strength training + aerobic (150 min/week moderate intensity) — reduces DAS28, improves HAQ and cardiovascular risk
Physiotherapy: Range of motion exercises, splinting (night splints for wrists), adaptive devices, joint protection education
Occupational Therapy: Joint protection strategies, assistive devices (jar openers, raised toilet seats), vocational adaptation
Smoking cessation: Reduces disease activity, improves DMARD response, lowers CV risk
Diet: Mediterranean diet — anti-inflammatory; omega-3 supplementation may modestly help; avoid obesity (increases inflammatory load)
Psychological support: CBT for pain management; depression screening (PHQ-9); support groups
Foot orthotics: For MTP subluxation, valgus deformities; custom insoles reduce foot pain and improve gait

🔪 Surgical Indications

Total joint replacement (hip, knee, shoulder) — severe erosive disease with refractory pain and functional impairment; hip/knee most commonly
Synovectomy — chronic synovitis unresponsive to medical therapy in a single joint
Tendon repair — extensor tendon rupture (little finger → 4th → 3rd); early repair gives better results
Wrist arthrodesis — severe wrist destruction with pain; sacrifices motion but eliminates pain
C1-C2 fusion — atlantoaxial subluxation with myelopathy
MCP arthroplasty — silicone implants for severe MCP destruction

⚡ Rapid Fire — Management

MTX mechanism: Inhibits DHFR → folate antagonism → anti-inflammatory; always give folic acid with it
EULAR 2025: Remove prognostic stratification — MTX failure = go to bDMARD
Certolizumab pegol = safest anti-TNF in pregnancy (no Fc portion → no transplacental transfer)
Latent TB must be treated before starting any biologic
In sustained remission: Taper, do NOT stop — stopping → flare in most patients within 1 year
Triple therapy (MTX + SSZ + HCQ) is not recommended per EULAR 2025 — no proven superiority over MTX + GC; worse radiographic outcomes

➡️ Next up: Section 7 — Monitoring & Counseling. Disease activity scores decoded, drug toxicity monitoring schedules, vaccination requirements, and patient education scripts.

📊

Monitoring & Counseling

Disease activity scores · Drug toxicity · Vaccinations · Patient education

📐 Disease Activity Assessment Tools

DAS28 — Disease Activity Score (28 joints)

DAS28 = 0.56×√(TJC28) + 0.28×√(SJC28) + 0.70×ln(ESR) + 0.014×PGA

Interpretation: >5.1 = High disease activity | 3.2–5.1 = Moderate | 2.6–3.2 = Low | <2.6 = Remission

⚠️ Limitation: CRP/ESR blunted by IL-6R inhibitors and JAKi → DAS28 may overestimate remission. Prefer CDAI or SDAI with these drugs. DAS28 weighted on tender joints (subjective) — fibromyalgia can falsely elevate it.

CDAI — Clinical Disease Activity Index

CDAI = SJC28 + TJC28 + PGA (0–10) + EGA (0–10)

Interpretation: >22 = High | 10–22 = Moderate | 2.8–10 = Low | ≤2.8 = Remission

✅ No labs required — bedside calculation. Not affected by IL-6R inhibitor. Preferred in clinical practice.

Boolean Remission Criteria (ACR-EULAR 2022 Revision)

Tender joint count ≤1 AND Swollen joint count ≤1 AND CRP ≤1 mg/dL AND Patient Global Assessment ≤2 cm (0–10)

ALL 4 criteria must be met simultaneously — most stringent definition. OR SDAI ≤3.3. Preferred definition for clinical trials and guideline endpoints (Per EULAR 2025 and 2022 ACR/EULAR revision).

HAQ-DI — Health Assessment Questionnaire Disability Index

8 categories (dressing, arising, eating, walking, hygiene, reach, grip, activities) Score 0–3 per category → Mean = 0–3

0 = No disability | 1 = Mild | 2 = Moderate | 3 = Severe disability
Primary measure of functional disability and response in clinical trials

🔬 Drug Toxicity Monitoring Schedule

Drug	Baseline Tests	Monitoring Frequency	Key Toxicity to Watch
MTX	CBC, LFTs, creatinine, CXR, HBV/HCV, beta-hCG	Monthly × 6 months → q6–12 weeks	Hepatotoxicity, myelosuppression, pneumonitis (stop if ILD worsens)
Leflunomide	CBC, LFTs, HBV/HCV	Monthly × 6 months → q2–3 months	Hepatotoxicity, peripheral neuropathy; cholestyramine washout if pregnant
Sulfasalazine	CBC, LFTs, G6PD level	q2–4w × 3 months → q3 months	Granulocytopenia, haemolytic anaemia (G6PD deficient)
Hydroxychloroquine	Eye exam baseline (if >40 or prior eye disease)	Annual OCT + visual field testing	Irreversible macular retinopathy (dose >5 mg/kg; duration >5 years = risk)
Anti-TNF	TB screening, HBV/HCV, CBC, ANA	LFTs periodically; CBC if symptoms	TB reactivation, serious bacterial infections, demyelination, drug-induced lupus
Rituximab	CBC, HBV/HCV, Quantiferon	CBC at regular intervals; IgG levels	PML (JC virus), HBV reactivation, persistent B-cell depletion
Tocilizumab	TB, CBC, LFTs, lipids	LFTs, CBC, lipids regularly	LFT elevation, neutropenia, bowel perforation (GI pathology history)
JAK inhibitors	TB, CBC, LFTs, lipids, creatinine	CBC, LFTs, lipids q4–8w initially → regularly	Herpes zoster (↑ 2-5×), lipid elevation, VTE, MACE risk (tofacitinib high-CV)
Glucocorticoids	BP, BMI, fasting glucose, DEXA if chronic use	BP, glucose periodically; annual DEXA	Osteoporosis, DM, HPA suppression, cataracts, avascular necrosis

🟢 Osteoporosis Prevention in RA on GC

All patients on GC ≥3 months should receive: Calcium 1000–1500 mg/day + Vitamin D 800–2000 IU/day. If prednisone ≥7.5 mg/day for ≥3 months AND any fragility fracture OR T-score ≤-2.5 → Add bisphosphonate (alendronate 70 mg weekly or zoledronic acid 5 mg annually). Per ACR 2022 GC-induced osteoporosis guidelines.

💉 Vaccination in RA Patients on DMARDs

Vaccine	Recommendation	Timing / Notes
Influenza (inactivated)	✅ Recommended annually	Safe on all DMARDs; slightly reduced immunogenicity on MTX, rituximab
Pneumococcal (PCV-15/20 + PPSV23)	✅ Strongly recommended	Immunocompromised schedule; repeat PPSV23 after 5 years
Herpes Zoster (Shingrix — recombinant subunit)	✅ Recommended (esp. on JAKi)	2 doses 2–6 months apart; preferred over live Zostavax on immunosuppressants
COVID-19 mRNA vaccines	✅ Recommended	Hold MTX 1–2 weeks post-dose if possible (improves immunogenicity); space rituximab and vaccines by ≥4 weeks
Hepatitis B	✅ Recommended if seronegative	Complete before starting biologics; use high-dose formulation if on immunosuppressants
Live attenuated vaccines (MMR, varicella, nasal flu, Zostavax, yellow fever)	🔴 CONTRAINDICATED	While on any biologic, JAKi, or significant immunosuppression. Give ≥4 weeks BEFORE starting or ≥6 months AFTER rituximab

🗣️ Patient Counseling — Key Points

What to Tell Your RA Patient (Plain Language)

"RA is a lifelong condition, but it is very manageable." — Set realistic expectations; emphasize that modern treatments can achieve remission in most patients
On Methotrexate: "Take it once a week only — NOT daily. Always take folic acid on the other 6 days. Avoid alcohol. Use effective contraception — both men AND women — while on MTX and for 3 months after stopping."
On Biologics: "You'll have a slightly higher infection risk. Get vaccinations updated before starting. Avoid crowded places during flu season. See a doctor immediately if you develop fever, chills, or unusual infections."
On Glucocorticoids: "We use these for a short time only. Long-term use causes bone loss, weight gain, diabetes. Never stop them suddenly."
Lifestyle: Quit smoking (worsens RA and reduces drug response). Exercise daily — it's as important as medication. Mediterranean diet. Maintain healthy weight.
Morning stiffness: "Warm showers and gentle movement in the morning help. Plan important activities for mid-morning when stiffness has improved."
Joint protection: Avoid forceful gripping; use assistive devices; distribute load across larger joints when possible
When to call immediately: Sudden severe joint pain in one joint (may be infected), fever >38°C, difficulty breathing, sudden neck pain with arm weakness
Mental health: Depression affects 20–30% of RA patients. It worsens pain perception and disease outcomes. Ask for help early.
Monitoring: Regular blood tests are non-negotiable while on DMARDs — not optional. Even if feeling well, liver/blood tests can be abnormal silently

⚡ Rapid Fire — Monitoring

DAS28 remission = <2.6; Low disease activity = 2.6–3.2; Goal = remission (early RA) or at least LDA (established)
Boolean remission (EULAR 2025): TJC≤1, SJC≤1, CRP≤1 mg/dL, PGA≤2 cm (revised from 1 cm in 2022)
HCQ retinopathy risk: Duration >5 years AND/OR dose >5 mg/kg/day
PML with rituximab = JC virus reactivation — rare but fatal; check JC antibody status before use
Live vaccines are contraindicated while on biologics/JAKi

➡️ Next up: Section 8 — Mastery Check. The 10 "must-know" facts, classic exam traps, and 2 board-style questions with full explanations.

🏆

Mastery Check

Must-know facts · Exam traps · Board-style questions

⚠️ One-Line Summary

RA is a chronic, systemic, autoimmune inflammatory arthritis driven by Th1/Th17 cells and B cells targeting citrullinated peptides (via ACPA), causing progressive joint destruction through TNF-α/IL-6/pannus/osteoclast activation, managed with early MTX + GC escalating to bDMARDs/JAKi per a treat-to-target (T2T) strategy aiming for DAS28 <2.6.

⭐ 10 Must-Know Facts for Every Exam

Anti-CCP antibody has ~97% specificity for RA — the most specific test
RA is the most common inflammatory arthritis; OA is the most common arthritis overall
RA SPARES DIP joints and the lumbar spine (unlike OA and SpA respectively)
Morning stiffness >1 hour = inflammatory (RA); <30 min = degenerative (OA)
Felty's syndrome = RA + splenomegaly + neutropenia — highest lymphoma risk
Methotrexate is the anchor DMARD; ALWAYS co-prescribe folic acid (5 mg/week) to reduce toxicity
EULAR 2025: Start DMARDs immediately on diagnosis; target remission within 6 months
No. 1 cause of death in RA = Cardiovascular disease (CVD risk is 2× general population)
Latent TB MUST be treated before starting any biologic DMARD
Stopping DMARDs in remission leads to flares in most patients within 1 year — TAPER, don't stop (EULAR 2025)

🎯 Classic Exam Traps

The Trap	The Answer
Patient with positive RF + joint pains → "Diagnose RA"	🔴 RF alone is NOT diagnostic. 5% of normals are RF+. Need clinical criteria + anti-CCP + exclude mimics
RA patient develops acute single hot joint → "Flare"	🔴 Aspirate the joint! Septic arthritis must be excluded first — especially if on biologics/JAKi
Patient on MTX stops folic acid because "it blocks MTX"	🔴 Folic acid does NOT reduce MTX efficacy — only reduces mucositis, hepatotoxicity, myelosuppression. ALWAYS co-prescribe
Prescribing MTX daily instead of weekly	🔴 MTX in RA is given ONCE WEEKLY. Daily dosing (cancer dosing) causes severe toxicity. Classic prescription error
Giving live vaccine to patient starting adalimumab next week	🔴 Live vaccines must be given ≥4 weeks BEFORE biologics. Once on biologics = NO live vaccines
Patient on tocilizumab with DAS28 <2.6 → "In remission"	⚠️ IL-6 inhibitors blunt CRP/ESR independently → DAS28 is unreliable. Use CDAI/SDAI or Boolean criteria
"RA is only a joint disease"	🔴 RA is systemic — CVD, ILD, vasculitis, lymphoma, renal amyloid, anaemia — all major EAMs with mortality impact
Atlantoaxial subluxation risk only in late disease	🔴 Can occur at any stage. ALWAYS check C-spine before GA/intubation in RA — ask about symptoms of myelopathy

📝 Board-Style Practice Questions

Q1. A 38-year-old woman presents with 8 weeks of pain and swelling in both hands, particularly in the MCP and PIP joints bilaterally, with morning stiffness lasting ~90 minutes. Her anti-CCP antibody is 3× ULN, RF is weakly positive, and ESR is 65 mm/hr. X-rays show only periarticular osteopenia. What is the 2010 ACR/EULAR score and what should be initiated?

Diagnosis Level 4 Source: ACR/EULAR 2010 Criteria + EULAR 2025

A) Score 5 — seronegative RA — start HCQ alone

B) Score 8 — Definite RA — start MTX + short-term GC immediately

C) Score 6 — possible RA — watchful waiting and repeat in 3 months

D) Score 8 — Definite RA — start anti-TNF agent immediately as first-line

✅ Answer: B — Score 8, Start MTX + GC

Score calculation: Joint involvement (>10 small joints = 5pts) + Serology (high positive anti-CCP ≥3×ULN = 3pts) + Acute phase reactants (ESR elevated = 1pt) + Duration ≥6 weeks (1pt) = 10/10 (or 8 if only 4–10 small joints; 3pt serology + 1pt APR + 1pt duration + 3pt joints = 8). Score ≥6 = Definite RA. Per EULAR 2025 Rec #1: Start DMARDs immediately. MTX is first-line (Rec #4). Anti-TNF is Phase II — not first-line. HCQ alone is inadequate for established RA.

💡 Teaching Point: Always calculate the score explicitly. "Possible RA with watchful waiting" is no longer acceptable — early treatment prevents irreversible joint damage.

Q2. A 55-year-old male with 8-year history of seropositive RA on methotrexate 20 mg/week is started on adalimumab after inadequate response. Four months later, he develops a productive cough, low-grade fever, and night sweats. His QuantiFERON test before starting adalimumab was negative. HRCT chest shows upper lobe nodules with cavitation. What is the most likely diagnosis and what error was made?

Complication Level 6 Source: EULAR 2025 + Infection guidelines

A) RA-associated ILD — continue adalimumab and add prednisolone

B) Pneumonia — start amoxicillin and continue adalimumab

C) Pulmonary tuberculosis (TB reactivation) — stop adalimumab, start anti-TB therapy

D) Rheumatoid nodules — no change in therapy needed

✅ Answer: C — TB Reactivation

Anti-TNF agents (especially infliximab and adalimumab, which are monoclonal antibodies) cause reactivation of latent TB by impairing granuloma integrity — TNF-α is essential for granuloma maintenance. Even if the QuantiFERON was negative (10–15% false negative rate), the clinical picture of upper lobe cavitating disease + constitutional symptoms in a patient on anti-TNF is TB until proven otherwise. The error: A single negative QuantiFERON does not fully exclude latent TB. IGRA has a false-negative rate, especially in immunocompromised patients. Some guidelines recommend Mantoux AND QuantiFERON together. Adalimumab must be STOPPED immediately; anti-TB treatment initiated. Adalimumab can be resumed after 2 months of adequate anti-TB therapy in most guidelines.

💡 Teaching Point: Anti-TNF monoclonal antibodies carry higher TB risk than etanercept (TNF receptor fusion protein) because they bind soluble AND membrane-bound TNF, which is critical for granuloma maintenance. Always screen with highest sensitivity possible before biologics.

➡️ Next up: Section 9 — Quick Revision. The 5-minute version, mega-mnemonic, comparison table, and 10 spaced-repetition flashcards.

⚡

Quick Revision — The Fast Sheet

5-minute review · Mega-mnemonic · Revision table · Flashcards

⚡ 5-Minute Complete RA Review

WHAT IS RA? Chronic systemic autoimmune inflammatory arthritis. Most common inflammatory arthritis. 0.5–1% prevalence. F:M = 3:1. Peaks 25–55 yrs. PATHOGENESIS: HLA-DRB1 (shared epitope) + Smoking → PAD4 activation → Citrullination → ACPA → CD4+ Th1/Th17 → TNF-α / IL-6 / IL-17 → Pannus (invasive synovium) → MMPs (cartilage) + RANKL (osteoclasts = bone erosion) JOINTS: Symmetrical, small joints (MCP, PIP, Wrist, MTP) → SPARES DIP, lumbar spine, SI joints Morning stiffness >1 hour | Squeeze test + | Boggy synovitis | Ulnar deviation EXTRA-ARTICULAR: Nodules (30%) | ILD (UIP/NSIP) | Pericarditis | Anaemia | Felty's | C-spine #1 cause of death = Cardiovascular disease DIAGNOSIS: RF: Sens 70%, Spec 75% | Anti-CCP: Sens 67%, Spec 97% 2010 ACR/EULAR criteria: Score ≥6/10 = Definite RA Joints (0-5) + Serology (0-3) + APR (0-1) + Duration ≥6w (0-1) Imaging: X-ray → erosions (late) | USS power Doppler → synovitis | MRI → earliest MANAGEMENT (EULAR 2025): Phase I: MTX (10–25 mg/week PO/SQ) + Short-term GC → evaluate at 3m and 6m Phase II (MTX failure): Add bDMARD (anti-TNF/IL-6Ri/abatacept/rituximab) OR JAKi (after careful risk assessment — CV, malignancy, VTE) Phase III (bDMARD failure): Switch bDMARD class OR second anti-TNF Remission: TAPER (do NOT stop) — stopping = flare in most within 1 year TARGET: DAS28 <2.6 (remission) | Boolean: TJC≤1, SJC≤1, CRP≤1, PGA≤2cm MONITORING: MTX → CBC+LFTs monthly×3→q12w | HCQ → Annual retinal OCT TB screen before ALL biologics/JAKi | No live vaccines on immunosuppressants Herpes zoster prophylaxis (Shingrix) for JAKi patients

🧠 Mega-Mnemonic — Complete RA

RHEUMATOID

RRF + Anti-CCP (serology); Rheumatoid nodules (30–40%); highest RF titre = worse prognosis

HHLA-DRB1 Shared Epitope (genetic risk); Hand deformities (swan-neck, boutonnière, Z-thumb, ulnar deviation)

EErosions (hallmark of structural damage on X-ray); Eye disease (KCS, episcleritis, scleritis)

UUlnar deviation (MCPs) + Ulnar styloid erosion; Urgent: Atlantoaxial subluxation (C1-C2) 🔴

MMethotrexate (first-line DMARD; + folic acid always); Morning stiffness >1 hour

AAnti-CCP (97% specific); Anaemia of chronic disease (#1 haematologic); Atlantoaxial subluxation 🔴

TTNF-α / IL-6 / IL-17 (cytokine triad); Tenosynovitis; Treat-to-Target (T2T strategy)

OOsteoporosis (periarticular→generalized); +Bisphosphonate if on GC >3 months

IILD (UIP/NSIP — exclude before MTX/LEF); Infections (risk with all DMARDs; screen TB first)

DDAS28 (disease activity score; remission <2.6); Deformities + Disability (target of T2T)

📊 Comparison: RA vs OA vs PsA vs SLE Arthritis

Feature	RA	OA	PsA	SLE Arthritis
Morning stiffness	>1 hour	<30 min	Variable	Variable
Joints affected	MCP, PIP, Wrist, MTP	DIP, 1st CMC, Hip, Knee	DIP (sausage digit), Sacroiliac	MCP, PIP, Wrist (similar to RA)
DIP involvement	❌ Spared	✅ Heberden's nodes	✅ Classic	❌ Usually spared
Synovitis type	Boggy (synovial fluid)	Hard/bony (osteophytes)	Synovitis + Enthesitis	Jaccoud's (reducible, non-erosive)
Serology	RF+, Anti-CCP+ (70%, 67%)	Negative	RF negative (seronegative)	ANA+, anti-dsDNA+, low C3/C4
X-ray	Erosions, periarticular osteopenia	Osteophytes, sclerosis	"Pencil in cup"; fluffy periostitis	No erosions (Jaccoud's)
Skin	Nodules, purpura	None	Psoriasis, nail pitting, onycholysis	Malar rash, photosensitivity, discoid
Systemic features	Common (ILD, CVD, etc.)	Absent	Uveitis, IBD, psoriasis	Nephritis, seizures, serositis
First-line Rx	MTX + GC	NSAIDs, Paracetamol, Physio	MTX (skin+joints); anti-TNF (severe)	HCQ + MTX; lupus-specific

🃏 Spaced-Repetition Flashcards (Click to Reveal)

Q: What is the most specific antibody in RA and its approximate specificity?

Anti-CCP (ACPA) — specificity ~97%

Tap to reveal

Q: What joints does RA characteristically SPARE that help differentiate it from OA?

DIP joints (unlike OA with Heberden's nodes) and lumbar/thoracic spine (unlike AS)

Tap to reveal

Q: What is Felty's Syndrome?

RA + Splenomegaly + Neutropenia (triad). Highest risk of lymphoma among RA subtypes.

Tap to reveal

Q: Why must folic acid always be co-prescribed with methotrexate in RA?

MTX inhibits dihydrofolate reductase → folate deficiency → mucositis, hepatotoxicity, myelosuppression. Folic acid supplementation reduces these toxicities without reducing efficacy.

Tap to reveal

Q: What is the minimum 2010 ACR/EULAR score to classify as definite RA?

Score ≥6/10 (maximum 10 points across 4 domains: joints, serology, acute phase reactants, symptom duration)

Tap to reveal

Q: What is the number one cause of death in RA patients?

Cardiovascular disease — RA patients have 2× the risk of coronary artery disease and atherosclerosis compared to the general population

Tap to reveal

Q: Which anti-TNF biologic is safest in pregnancy and why?

Certolizumab pegol — it lacks an Fc portion (PEGylated Fab fragment only), so it cannot cross the placenta via FcRn receptors. No fetal exposure.

Tap to reveal

Q: What is the HLA allele most strongly associated with RA and what is the "shared epitope"?

HLA-DRB1 alleles (most importantly *0401, *0404 in Europeans). The shared epitope = conserved amino acid sequence (positions 70–74) in the HLA-DR β-chain that facilitates citrullinated peptide presentation.

Tap to reveal

Q: Per EULAR 2025, should DMARDs be stopped when a patient achieves sustained remission?

NO — DMARDs should be continued but dose/interval may be TAPERED after ≥6 months of sustained remission. Stopping leads to flares in most patients within 1 year.

Tap to reveal

Q: What must be done BEFORE starting any biologic DMARD in RA?

Screen and treat latent TB (QuantiFERON/Mantoux), screen for HBV/HCV (reactivation risk with rituximab/anti-TNF), update vaccinations (live vaccines ≥4 weeks before starting), baseline CBC, LFTs, creatinine, lipids.

Tap to reveal

➡️ Next up: Section 10 — Quiz Bank. 7 Levels × 30 questions each, from Foundation Recall to Fellowship-level expert cases.

📝

Quiz Bank — 7 Levels

Foundation → Expert · Progressive difficulty · Full explanations · Bloom's tagged

📝 Quiz Architecture

Each level contains representative questions. Click any level header to expand. All questions include correct answer, detailed explanation (≥3 lines), and a teaching point. Tags: [Topic] [Bloom's Level] [Difficulty].

Level 1

Foundation — Recall & Basic Definitions

True/False · Simple MCQ

▼

1.1 Which antibody has the highest specificity (~97%) for Rheumatoid Arthritis?

SerologyBloom's L1 — Recall

A) Antinuclear Antibody (ANA)

B) Rheumatoid Factor (RF)

C) Anti-Cyclic Citrullinated Peptide (Anti-CCP)

D) Anti-dsDNA antibody

✅ Answer: C

Anti-CCP (ACPA) has a sensitivity of ~67% and specificity of ~97% for RA — making it the most specific serological test. RF is positive in ~70% of RA patients but also in SLE, Sjögren's, HCV, SBE, and ~5% of normal individuals. ANA is positive in ~30% of RA patients (low titre, non-specific). Anti-dsDNA is specific for SLE, not RA.

💡 Teaching Point: When both RF and anti-CCP are positive, the specificity for RA approaches 99%. Anti-CCP can also appear up to 10 years before clinical RA — making it useful for identifying pre-RA populations.

1.2 True or False: Rheumatoid Arthritis characteristically involves the distal interphalangeal (DIP) joints as an early feature.

Joint involvementBloom's L1 — Recall

A) FALSE — RA characteristically SPARES DIP joints

B) TRUE — DIP joints are frequently involved in early RA

✅ Answer: FALSE

RA characteristically involves MCPs, PIPs, wrists, and MTPs symmetrically — but SPARES DIP joints. DIP involvement is characteristic of Osteoarthritis (Heberden's nodes) and Psoriatic Arthritis. This is a classic exam discriminator. Remembering the "DIP" joints in RA = Doesn't Involve Proximally-distal pattern = DIP spared, PIP involved.

💡 Teaching Point: If a patient presents with inflammatory arthritis predominantly affecting DIP joints, consider Psoriatic Arthritis (check nails, skin) or Erosive OA, NOT RA.

1.3 What is Felty's syndrome?

Extraarticular featuresBloom's L1 — Recall

A) RA + pleural effusion + neutropenia

B) RA + splenomegaly + neutropenia

C) RA + lymphoma + thrombocytopenia

D) RA + pericarditis + anaemia

✅ Answer: B

Felty's syndrome is the triad of RA + Splenomegaly + Neutropenia. It occurs in patients with long-standing, typically seropositive (high RF titre) RA. The neutropenia predisposes to serious bacterial infections, and patients with Felty's syndrome have a 2–4× increased risk of developing non-Hodgkin's B-cell lymphoma. Its incidence has declined significantly with modern DMARD therapy.

💡 Teaching Point: The "Three S" of Felty's: Seropositive, Splenomegaly, and Suppressed (WBC) — in a patient with long-standing RA.

Level 2

Comprehension — Mechanisms & Connections

MCQ with reasoning · Matching

▼

2.1 Why is folic acid co-prescribed with methotrexate in RA? Which aspect of MTX's mechanism does folic acid counteract?

PharmacologyBloom's L2 — Comprehension

A) Folic acid reduces MTX's absorption, keeping blood levels safe

B) Folic acid reverses MTX's anti-inflammatory mechanism, reducing efficacy

C) Folic acid replenishes the folate pathway suppressed by MTX, reducing toxicity without significantly impairing anti-inflammatory efficacy

D) Folic acid converts MTX to an inactive metabolite in the liver

✅ Answer: C

MTX inhibits dihydrofolate reductase (DHFR) → blocks tetrahydrofolate regeneration → depletes purines and thymidylate → anti-inflammatory AND anti-proliferative effects. In RA, the anti-inflammatory effect is thought to be largely via adenosine release rather than purely folate inhibition. Supplemental folic acid replenishes the depleted folate pool, reducing mucositis, hepatotoxicity, and myelosuppression, without substantially diminishing the anti-inflammatory effect. Multiple RCTs confirm folic acid supplementation does not reduce MTX clinical efficacy in RA.

💡 Teaching Point: The MTX dose in RA (7.5–25 mg/week) is a low-dose immune modulator — very different from high-dose cancer chemotherapy. Folic acid is mandatory in RA but NOT used in cancer regimens.

2.2 Which cytokine is primarily responsible for the elevation of CRP and ESR in RA, and which drug class directly targets this cytokine's receptor?

Pathogenesis · PharmacologyBloom's L2 — Comprehension

A) TNF-α — Anti-TNF agents (adalimumab, etanercept)

B) IL-6 — IL-6 receptor inhibitors (tocilizumab, sarilumab)

C) IL-17 — IL-17 inhibitors (secukinumab)

D) IL-1 — Anakinra (IL-1RA)

✅ Answer: B

IL-6 is the primary driver of the acute phase response in RA — it stimulates hepatic production of CRP, fibrinogen, serum amyloid A, and other APRs. It also drives the ESR elevation (via fibrinogen). Tocilizumab (IV/SQ) and sarilumab (SQ) are monoclonal antibodies against the IL-6 receptor (IL-6R). They dramatically suppress CRP and ESR, sometimes to below normal — even without complete clinical remission. This creates the important clinical pitfall: DAS28 (which includes CRP/ESR) underestimates disease activity in patients on IL-6R inhibitors or JAKi.

💡 Teaching Point: When a patient on tocilizumab has a DAS28 <2.6 based on CRP, always validate with clinical joint counts (CDAI/SDAI) or Boolean criteria. CRP is unreliable for disease monitoring with IL-6R inhibitors.

Level 3

Application — Simple Clinical Scenarios

Clinical vignette MCQ · Matching

▼

3.1 A 44-year-old woman newly diagnosed with RA (anti-CCP 4× ULN, 6 swollen MCPs bilaterally, ESR 72) asks about medication. She has no contraindications to any DMARD. Per EULAR 2025 guidelines, what is the most appropriate first-line treatment?

ManagementBloom's L3 — Application

A) Adalimumab (anti-TNF biologic) as first-line given high disease activity

B) Hydroxychloroquine monotherapy

C) Methotrexate + short-term glucocorticoids

D) Tofacitinib (JAK inhibitor) given her high ACPA titre

✅ Answer: C

Per EULAR 2025 Recommendation #4 and #5: MTX should be part of the first treatment strategy. Short-term glucocorticoids should be considered when initiating csDMARDs, used as bridging therapy while MTX takes effect (6–12 weeks), and tapered as rapidly as clinically feasible. Biologics (anti-TNF) and JAKi are Phase II treatments — added when Phase I fails at 3–6 months. No trial has shown superiority of bDMARDs over MTX+GC as initial therapy in early RA. High ACPA titre is a prognostic factor but does NOT change the initial treatment algorithm in EULAR 2025 (prognostic stratification was removed).

💡 Teaching Point: Even in high-disease-activity RA, MTX+GC is first-line because it achieves remission in a significant proportion of patients, is less expensive than biologics, and has a well-established safety profile. Reserve biologics for Phase II failure.

3.2 A patient with RA controlled on adalimumab for 2 years is planning to travel to an area where Yellow Fever vaccination is required. Can you give the yellow fever vaccine?

VaccinationBloom's L3 — Application

A) Yes — yellow fever is a standard travel vaccine and safe with adalimumab

B) Yes — but dose should be halved

C) No — Yellow Fever is a live attenuated vaccine, contraindicated while on biologics

D) Yes — yellow fever vaccine is not live so it is safe

✅ Answer: C

Yellow Fever vaccine (Stamaril, YF-Vax) is a live attenuated vaccine — ABSOLUTELY CONTRAINDICATED in patients on biologics, JAKi, or significant immunosuppression. Live vaccines can cause disseminated infection in immunocompromised patients. This includes: MMR, Varicella/Zoster (Zostavax — live), Nasal Flu (LAIV), Yellow Fever, Typhoid (live oral Ty21a), BCG. Safe alternatives should be explored: if travel is essential, adalimumab may need to be temporarily held for a sufficient period before vaccination (varies by biologic half-life — typically 3–5 half-lives; for adalimumab t½ ~14 days → hold ~5–10 weeks), consult infectious disease/tropical medicine.

💡 Teaching Point: INACTIVATED vaccines (influenza injectable, pneumococcal, hepatitis B, Td, inactivated polio, Shingrix/recombinant herpes zoster) are SAFE on biologics. LIVE vaccines = NEVER on biologics.

Level 4

Analysis — Lab + Imaging Interpretation

Data interpretation · Complex vignettes

▼

4.1 A 50-year-old woman with a 12-year history of RF-positive RA (currently on MTX 20 mg/week + etanercept) presents with progressive breathlessness over 6 months. HRCT chest shows bilateral basal predominant ground-glass opacities with subpleural sparing and traction bronchiectasis. What is the most likely pattern of ILD and which DMARDs should be avoided?

ILD · ImagingBloom's L4 — Analysis

A) UIP pattern — avoid rituximab, continue etanercept

B) NSIP pattern — avoid MTX and leflunomide; consider switching to abatacept

C) DIP pattern — continue current regimen unchanged

D) LIP pattern — hydroxychloroquine is first-line treatment

✅ Answer: B

The HRCT pattern described — bilateral basal ground-glass opacities, subpleural sparing, traction bronchiectasis — is classic for NSIP (Non-Specific Interstitial Pneumonia), the most common ILD pattern in RA (followed by UIP). UIP (Usual Interstitial Pneumonia) shows honeycombing and lacks subpleural sparing. In RA-ILD, MTX and leflunomide should be avoided/discontinued as both can cause drug-induced pneumonitis that is difficult to distinguish from RA-ILD and can worsen existing ILD. Abatacept has emerging evidence for stabilizing RA-ILD (RECOURSE trial data). Rituximab is also used. EULAR 2025 mentions nintedanib as potentially slowing ILD progression (INBUILD data).

💡 Teaching Point: When a patient on MTX develops new pulmonary symptoms, ALWAYS stop MTX first (MTX pneumonitis vs RA-ILD can be clinically indistinguishable). HRCT pattern helps distinguish: Ground-glass (drug-induced, NSIP) vs Honeycombing (UIP — usually irreversible).

4.2 A 62-year-old male RA patient on tofacitinib 5 mg twice daily develops a painful unilateral vesicular rash in a dermatomal distribution. What complication is this and how does tofacitinib contribute?

JAKi complicationsBloom's L4 — Analysis

A) Drug-induced photosensitivity — switch to a different drug class

B) Contact dermatitis from subcutaneous injection site

C) Herpes Zoster reactivation — JAKi increase this risk 2–5× by impairing lymphocyte-mediated viral surveillance

D) Psoriatic flare triggered by tofacitinib

✅ Answer: C

JAK inhibitors, particularly tofacitinib, increase the risk of Herpes Zoster reactivation by 2–5× compared to background RA risk. JAK1/JAK3 inhibition impairs IFN-γ signaling and lymphocyte surveillance, reducing control over latent VZV. Treatment: oral valaciclovir or aciclovir (adjust dose for renal function). Tofacitinib should be held during active zoster. Prevention: Shingrix (recombinant zoster vaccine, 2 doses) is recommended BEFORE starting JAKi in patients ≥50 years or those at high risk. Shingrix is a recombinant (non-live) vaccine — SAFE with JAKi (unlike live Zostavax).

💡 Teaching Point: Among all DMARDs, JAK inhibitors carry the highest risk of herpes zoster. Upadacitinib (selective JAK1) may have a higher zoster rate than baricitinib. Vaccinate with Shingrix before starting JAKi whenever possible.

Level 5

Synthesis — Complex Multi-System Cases

Extended vignettes · Management MCQ

▼

5.1 A 34-year-old woman with seropositive RA (DAS28 = 5.8) is on MTX 20 mg/week for 6 months with inadequate response. She is 8 weeks pregnant (confirmed by obstetric USS). Her rheumatologist needs to redesign her treatment. What is the most appropriate management?

Pregnancy · ManagementBloom's L5 — Synthesis

A) Continue MTX (it is the most effective DMARD and benefit outweighs risk)

B) Switch to leflunomide (safer than MTX in pregnancy)

C) Stop MTX immediately (teratogen), start hydroxychloroquine + prednisolone, consider certolizumab pegol for active disease

D) Stop all DMARDs as pregnancy naturally suppresses RA

✅ Answer: C

MTX must be stopped immediately — it is a known teratogen (FDA Pregnancy Category X / FKSH Teratogen Class D). Risk: fetal loss, neural tube defects, craniofacial abnormalities. If MTX is stopped at 8 weeks gestation: the fetus has already been exposed during organogenesis — urgent obstetric and geneticist consultation is needed. Leflunomide is also Category X — absolutely contraindicated. Safe in pregnancy: Hydroxychloroquine (antimalarial; continue throughout pregnancy), sulfasalazine (+ high-dose folic acid), low-dose prednisolone, certolizumab pegol (preferred biologic — no placental transfer). About 75% of RA patients improve during pregnancy; but 90% flare postpartum. Continue certolizumab throughout pregnancy if needed — no neonatal immunosuppression (no IgG to cross placenta).

💡 Teaching Point: The ONE biologic specifically studied and approved for pregnancy in RA is certolizumab pegol (CRIB study). All other anti-TNFs should generally be stopped at the end of 2nd trimester (some safety data, but transplacental transfer occurs with Fc-containing antibodies). JAKi = absolute contraindication in pregnancy.

Level 6

Evaluation — Guideline-Based Decisions

USMLE Step 2 style · Critical reasoning

▼

6.1 A 68-year-old male smoker with RA and a history of myocardial infarction (6 months ago) has failed MTX (inadequate response at 6 months). His DAS28 is 5.2. Per EULAR 2025, which of the following is the MOST appropriate next step?

EULAR 2025 · CV riskBloom's L6 — Evaluation

A) Start tofacitinib 5 mg twice daily (most efficacious)

B) Add adalimumab or abatacept to MTX (bDMARD preferred given high CV and malignancy risk factors for JAKi)

C) Switch to baricitinib (selective JAK1/2, lower CV risk than tofacitinib)

D) Start triple therapy (MTX + HCQ + SSZ) and reassess

✅ Answer: B

Per EULAR 2025 Recommendation #6: "JAK inhibitors may be considered, but pertinent risk factors must be taken into account." The footnote to the EULAR 2025 algorithm specifically lists: Age >65, current/past smoking, history of cardiovascular events (MACE), history of malignancy, history of NMSC, thromboembolic risk factors, and taking hormonal contraceptives as factors precluding preferential JAKi use. This patient has multiple contraindications to JAKi (age 68, smoker, recent MI). bDMARDs are preferred. Abatacept may be particularly appropriate in an elderly patient with CV disease given its good tolerability profile. Triple therapy was removed from EULAR 2025 recommendation (no superiority over MTX+GC; worse radiographic outcomes in NORD-STAR data).

💡 Teaching Point: The ORAL Surveillance trial (2022) showed tofacitinib vs anti-TNF in patients with CV risk factors → ↑MACE, ↑malignancy, ↑PE/DVT with tofacitinib. EULAR 2025 maintains caution on JAKi in CV-risk patients, despite mixed data from observational studies. When in doubt, choose bDMARD first.

6.2 A patient with RA in sustained remission (DAS28 1.8 for 14 months) on MTX + adalimumab asks to stop her medications. Per EULAR 2025, what is the most evidence-based recommendation?

EULAR 2025 · RemissionBloom's L6 — Evaluation

A) Stop all DMARDs — she is in remission and may not need them further

B) Stop adalimumab only, continue MTX indefinitely

C) Continue both DMARDs but consider dose reduction or interval increase of adalimumab; explain stopping leads to flares in most patients within 1 year

D) Stop MTX first, observe for 3 months, then consider stopping adalimumab

✅ Answer: C

Per EULAR 2025 Recommendation #9: "After glucocorticoids have been discontinued and a patient is in sustained remission, continuation of DMARDs is recommended, but dose reduction may be considered." This represents a significant strengthening of the 2022 recommendation. Data consistently show that stopping DMARDs (both csDMARDs and bDMARDs) in remission leads to flares in the vast majority of patients within 12 months (PRESERVE, STRASS, OPTIMA trials). Dose reduction/interval extension is acceptable and may reduce costs and side effects while maintaining remission. The hierarchy: taper GC first (already done), then space bDMARD (e.g., adalimumab every 3 weeks, then monthly), lastly reduce MTX dose. Never stop everything simultaneously.

💡 Teaching Point: EULAR 2025 moved from "may consider stopping" → "continuation is recommended, dose reduction may be considered." Remission ≠ cure. Convey this clearly: "the disease is controlled by medication, not cured — stopping reverses the control."

Level 7

Expert / Fellowship — Advanced Pathophysiology

Complex multi-step vignettes · Research-level

▼

7.1 Which enzyme converts arginine to citrulline in RA, is encoded by the PADI4 gene, is activated by cigarette smoke in the lung and periodontal tissue, and represents the molecular nexus linking environmental triggers to ACPA generation — making it a potential therapeutic target?

Advanced PathogenesisBloom's L7 — Expert

A) Matrix Metalloproteinase-3 (MMP-3)

B) Caspase-1

C) Peptidylarginine Deiminase type 4 (PAD4)

D) RANKL (Receptor Activator of NF-κB Ligand)

✅ Answer: C — PAD4

Peptidylarginine Deiminase type 4 (PAD4) is encoded by the PADI4 gene and catalyzes the post-translational modification of arginine → citrulline (citrullination/deimination) in cellular proteins. This creates neo-antigens (fibrinogen, vimentin, α-enolase, collagen type II, keratin) — the targets of ACPA. PAD4 is upregulated by cigarette smoking, hypoxia, and infection (especially P. gingivalis). PADI4 polymorphisms are associated with a 2× RA risk (mainly in East Asian populations). PAD inhibitors (e.g., BB-Cl-amidine, GSK199) are under investigation as therapeutic agents that could interrupt the earliest step of RA pathogenesis — the generation of citrullinated neoantigens — potentially preventing ACPA formation itself.

💡 Teaching Point: Understanding PAD4 explains why periodontal disease (P. gingivalis — the only oral bacterium expressing its own PAD enzyme) is an RA risk factor. This is not just epidemiological correlation — it's mechanistically coherent: P. gingivalis PAD citrullinates host proteins → generates ACPAs → RA.

7.2 Per the EULAR 2025 update: What major change was made to the Phase II treatment algorithm compared to EULAR 2022, and what evidence led to this change?

EULAR 2025 UpdateBloom's L7 — Expert

A) Rituximab was added as first-line biologic option alongside anti-TNF agents

B) JAK inhibitors were removed from Phase II due to safety concerns

C) Prognostic factor stratification was abolished — MTX failure itself is now sufficient indication for bDMARD, regardless of RF/ACPA status, erosions, or disease activity level

D) Triple therapy (MTX+SSZ+HCQ) was added as an alternative to bDMARD in Phase II

✅ Answer: C

In EULAR 2022, patients failing Phase I (MTX+GC) were stratified: those WITH adverse prognostic factors (high disease activity, seropositive RF/ACPA, early erosions, failure of 2+ csDMARDs) went directly to bDMARD (old recommendation 8); those WITHOUT risk factors could try another csDMARD first (old recommendation 7). In EULAR 2025, this stratification was abolished. Reasons: (1) MTX failure itself carries poor prognosis regardless of baseline markers; (2) Low persistence rates of second csDMARD after MTX failure (low efficacy, high dropout — Erhardt DP et al, Arthritis Care Res 2019); (3) Evidence that adding csDMARD after MTX failure has much lower persistence than adding a bDMARD; (4) Biosimilar costs have fallen dramatically, making bDMARDs economically comparable to second csDMARD strategies in many health systems; (5) Generic tofacitinib now available. Result: All patients failing MTX+GC should proceed to bDMARD (Phase II) rather than trying another csDMARD round first. 98% of task force voted in favour of this change.

💡 Teaching Point: This is the MOST SIGNIFICANT CHANGE in EULAR 2025 vs 2022. On any exam or vignette asking about EULAR 2025, this change will be tested. "If MTX fails → ADD A bDMARD" — no more prognostic stratification needed.

🔗 Recommended Resources & Guideline Links

📄 EULAR 2025 RA Management Recommendations — Smolen JS et al. Annals of the Rheumatic Diseases 2026;85:991–1009
📄 2010 ACR/EULAR Classification Criteria for RA — Aletaha D et al. Arthritis Rheum 2010;62:2569–2581
📄 ACR 2021 Guideline for Treatment of RA — Fraenkel L et al. Arthritis Care Res 2021;73:924–939
📖 Harrison's Principles of Internal Medicine, 21e — Chapter 358: Rheumatoid Arthritis (Ankoor Shah, E. William St. Clair)
🧮 MDCalc DAS28 Calculator — mdcalc.com/das28 (also: CDAI, SDAI, 2010 ACR/EULAR criteria)
💊 EULAR Vaccination Recommendations for Autoimmune Inflammatory Diseases — Ann Rheum Dis 2023
🔬 StatPearls — Rheumatoid Arthritis 2023 — NCBI Bookshelf

✅ Module Complete!

You have completed the Rheumatoid Arthritis Masterclass. You now understand the molecular pathogenesis, the full clinical spectrum, how to apply 2010 ACR/EULAR classification criteria, the EULAR 2025 three-phase treatment algorithm, drug monitoring schedules, and can answer questions from Foundation to Fellowship level. Review the flashcards weekly, attempt the quiz at each level, and revisit this module before clinical rotations and board exams.

⬆️ Module 01 Complete. Next module: Systemic Lupus Erythematosus (SLE) — from complement pathways to lupus nephritis and antiphospholipid syndrome.